Acute and Chronic Macrophage Differentiation Modulates TREM2 in a Personalized Alzheimer’s Patient-Derived Assay
Open Access
- 17 May 2023
- journal article
- research article
- Published by Springer Nature in Cellular and Molecular Neurobiology
- Vol. 43 (6) , 3047-3060
Abstract
Neuroinflammation plays a pivotal role in the pathogenesis of Alzheimer`s disease (AD). Brain macrophage populations differentially modulate the immune response to AD pathology according to the disease stage. Triggering receptor expressed on myeloid cells 2 (TREM2) is known to play a protective role in AD and has been postulated as a putative therapeutic target. Whether, and to which extent TREM2 expression can be modulated in the aged macrophage population of the brain is unknown, emphasizing the need for a human, patient-specific model. Using cells from AD patients and matched controls (CO) we designed an assay based on monocyte-derived macrophages to mimic brain-infiltrating macrophages and to assess the individualized TREM2 synthesis in vitro. We systematically assessed the effects of short-term (acute—2 days) and long-term (chronic—10 days) M1- (LPS), M2- (IL-10, IL-4, TGF-β), and M0- (vehicle) macrophage differentiation on TREM2 synthesis. Moreover, the effects of retinoic acid (RA), a putative TREM2 modulator, on individualized TREM2 synthesis were assessed. We report increased TREM2 synthesis after acute M2- compared to M1-differentiation in CO- but not AD-derived cells. Chronic M2- and M0-differentiation however resulted in an increase of TREM2 synthesis in both AD- and CO-derived cells while chronic M1-differentiation increased TREM2 in AD-derived cells only. Moreover, chronic M2- and M0-differentiation improved the amyloid-β (Aβ) uptake of the CO-derived whereas M1-differentiation of the AD-derived cells. Interestingly, RA-treatment did not modulate TREM2. In the age of personalized medicine, our individualized model could be used to screen for potential drug-mediated treatment responses in vitro. Graphical Abstract Triggering receptor expressed on myeloid cells 2 (TREM2) has been postulated as a putative therapeutic target in Alzheimer’s disease (AD). Using cells from AD patients and matched controls (CO), we designed a monocyte-derived macrophages (Mo-MФs) assay to assess the individualized TREM2 synthesis in vitro. We report increased TREM2 synthesis after acute M2- compared to M1- macrophage differentiation in CO- but not AD-derived cells. Chronic M2- and M0- differentiation however resulted in an increase of TREM2 synthesis in both AD- and CO-derived cells while chronic M1-differentiation increased TREM2 in AD-cells onlyKeywords
Funding Information
- Charité - Universitätsmedizin Berlin
This publication has 65 references indexed in Scilit:
- Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunityScience, 2014
- TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post‐Mortem Temporal CorticesBrain Pathology, 2014
- An optimized Protocol for Human M2 Macrophages using M‐CSF and IL‐4/IL‐10/TGF‐β Yields a Dominant Immunosuppressive PhenotypeScandinavian Journal of Immunology, 2014
- Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseasesBiomarker Research, 2014
- Acute injury in the peripheral nervous system triggers an alternative macrophage responseJournal of Neuroinflammation, 2012
- All-transretinoic acid as a novel therapeutic strategy for Alzheimer’s diseaseExpert Review of Neurotherapeutics, 2009
- Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapyMolecular Psychiatry, 2004
- Impaired Differentiation of Osteoclasts in TREM-2–deficient IndividualsJournal of Experimental Medicine, 2003
- Evidence for defective retinoid transport and function in late onset Alzheimer's diseaseProceedings of the National Academy of Sciences, 2003
- Increased plasma levels of interleukin-1, interleukin-6 and α-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?Journal of Neuroimmunology, 2000